Community/Retail

The FDA approved Rextovy, a 4-mg over-the-counter naloxone nasal spray, expanding public access to a life-saving opioid overdose reversal medication and increasing the availability of nonprescription treatment options.

The indication is for complicated urinary tract infections (UTIs) caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options.

Chiadi Ndumele, MD, explains why the new American Heart Association (AHA)/American College of Cardiology (ACC) guideline addresses cardiovascular, kidney, and metabolic (CKM) disease as one interconnected syndrome.

Fátima Rodriguez, MD, explains how the new cardiovascular-kidney-metabolic (CKM) syndrome guideline addresses health equity, risk prediction, and the pharmacist's role in care.

The findings add to a growing body of evidence supporting metformin's role as a preventive strategy against postacute sequelae of COVID-19.

The ADA Scientific Sessions highlighted important advances across the diabetes treatment landscape.

When pharmacists and clinical decision support software work in tandem, the result is a powerful safety net that catches medication errors before they reach patients.

Phase 3 REIMAGINE data presented at ADA 2026 show the amylin–GLP-1 combination bests semaglutide monotherapy across type 2 diabetes stages, with implications for pharmacist-managed diabetes care.

Proactive, multidisciplinary strategies for managing drug shortages.

Cheeley takes listeners inside her clinical decision-making process—from statin intolerance to PCSK9 inhibitors to omega-3s—and explains why patient buy-in is as important as the prescription itself.

The integrated CGM is now indicated for individuals 2 years and older who do not use insulin.

At ACTHIV 2026, Jaimee Colvin, MSN, APRN, FNP-C, outlined how provider knowledge gaps, entrenched stigma, and a lack of culturally representative outreach continue to drive the PrEP disparity among cisgender Black and Brown women.

Approval of teplizumab-mzwv in patients aged 8 to 17 years makes it the first disease-modifying therapy for children newly diagnosed with stage 3 type 1 diabetes.

This year’s guide, compiled from a national survey of 1700 practicing pharmacists, identifies the top recommended brands across 145 product categories, ranging from pediatric care to pain relief.

Korean and Asian manufacturers have used bemotrizinol widely in sunscreen formulations for many years.

Leaders unpack governance, SOP scalability, and payer hurdles in Cell and Gene Therapy Program Development, helping the cell and gene therapies community build sustainable programs.

TIMI Study Group investigators presented new VESALIUS-CV data showing that intensive LDL-C lowering with evolocumab reduces major cardiovascular events, reinforcing the "lower is better, earlier is better" approach to lipid management.

Probiotic and prebiotic supplements shape the gut microbiome and boost gastrointestinal health and immunity.

Jaimee Colvin, MSN, APRN, FNP-C, outlines the intentional, community-rooted, and representation-driven infrastructure required to scale PrEP access for cisgender women nationally.

What began as a modest survey has grown into one of the most trusted barometers of frontline pharmaceutical expertise in the country.

Correcting the misinformation around statins and cardiovascular disease, and reframing Lp(a) as a genetic condition, not a personal failure, can be a powerful clinical tool.

A post hoc analysis of ATTAIN-1 and ATTAIN-2 presented at ADA 2026 found orforglipron (Foundayo) significantly reduced body weight and waist circumference in women regardless of menopausal stage.

The landscape of cardiovascular prevention is shifting from a focus on surrogate biomarkers to a more granular, image-based assessment of actual disease burden.

Craig Beavers, PharmD, discusses transthyretin amyloidosis cardiomyopathy (ATTR-CM) red flags, treatment evidence, and how pharmacists can drive earlier diagnosis and improve patient outcomes.

Student pharmacists boost dermatology literacy in underserved communities, improving sunscreen habits, skin cancer warning recognition, and practical skin health self-care.

From prior authorization barriers to population health gaps, Cheeley explains why adherence — not initiation — is where pharmacists can make their biggest impact.

This week's episode covers the first-ever joint guidelines for cardiovascular-kidney-metabolic syndrome, key highlights from ASCO 2026 and ADA 2026, and new FDA approvals in diabetes, infectious diseases, and pain management.

Persistent HIV stigma, provider reluctance, and harmful misconceptions about who PrEP is for continue to prevent cisgender Black and Brown women from accessing lifesaving prevention.